(Las Vegas Nevada United States), DelveInsight’s “Graves’ Disease- Pipeline Insight, 2023” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in the Graves’ Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Over 8+ Companies and 10 + Pipeline Drugs for Graves Disease are in various stages of development, and their anticipated acceptance in the Graves Disease market would significantly increase market revenue.
Leading Graves Disease companies developing novel drug candidates to improve the Graves Disease treatment landscape includes Viridian Therapeutics, Immunovant Sciences GmbH, Apitope International NV, Sling Therapeutics, Novartis Pharmaceuticals and many others.
Promising Graves Disease pipeline therapies in various stages of development include Batoclimab, Linsitinib, VRDN-001, and many others.
Graves Disease Overview
Graves’ Disease (GD) is an autoimmune disease that primarily affects the thyroid gland. It may also affect multiple other organs, including the eyes and skin. It is the most common cause of hyperthyroidism. Graves’ disease is caused by thyroid-stimulating immunoglobulin (TSI), also known as thyroid-stimulating antibody (TSAb). B lymphocytes primarily synthesize Thyroid stimulating immunoglobulin within the thyroid cells, but it can also be synthesized in lymph nodes and bone marrow. B lymphocytes are stimulated by T lymphocytes which get sensitized by antigens in the thyroid gland. Thyroid-stimulating immunoglobulin binds with the thyroid-stimulating hormone (TSH) receptor on the thyroid cell membrane and stimulates the action of the thyroid-stimulating hormone. It stimulates both, thyroid hormone synthesis and thyroid gland growth, causing hyperthyroidism and thyromegaly. Several environmental factors, including pregnancy (mainly postpartum), iodine excess, infections, emotional stress, smoking, and interferon alfa, trigger immune responses in susceptible genes to eventually cause Graves’ disease.
Graves Disease Pipeline Analysis: Drug Profile
Batoclimab: Immunovant Sciences GmbH
Batoclimab (IMVT-1401) is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). The FcRn receptor facilitates IgG recycling. Batoclimab enhances the degradation of IgG by targeting FcRn and preventing endogenous IgG from binding. This increased catabolism of IgG may curtail the harmful immune response exhibited by auto-antibodies. In nonclinical studies and in clinical trials conducted, batoclimab was observed to reduce IgG antibody levels. High levels of pathogenic IgG antibodies drive a variety of autoimmune diseases and, as a result, the company believes that this product candidate has the potential to address a variety of IgG-mediated autoimmune diseases as a self-administered subcutaneous injection. The drug is currently being investigated in the Phase III stage of development for the treatment of Graves’ Disease.
Discover more about the emerging Graves Disease drugs @ Graves DiseaseTreatment Drugs
Graves Disease Pipeline Therapies and Key Companies
ARO-AAT: Arrowhead Pharmaceuticals
And many others
Graves Disease Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Graves Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.
Scope of the Graves Disease Pipeline Report
Key Graves Disease Companies: Viridian Therapeutics, Immunovant Sciences GmbH, Apitope International NV, Sling Therapeutics, Novartis Pharmaceuticals, and many others
Key Graves Disease Pipeline Therapies: Batoclimab, Linsitinib, VRDN-00, and many others
Find out more about the Graves Disease treatment options in development @ Graves Disease Clinical Trials
Table of Contents
1. Graves Disease Introduction
2. Graves Disease Executive Summary
3. Graves Disease Overview
4. Graves Disease Pipeline Therapeutics
5. Graves Disease Late-Stage Products (Phase III)
6. Graves Disease Mid-Stage Products (Phase II)
7. Graves Disease Early Stage Products (Phase I/II)
8. Graves Disease Preclinical Stage Products
9. Graves Disease Discovery Stage Products
10. Graves Disease Therapeutic Assessment
11. Graves Disease Inactive Products
12. Graves Disease Collaborations Assessment- Licensing / Partnering / Funding
13. Graves Disease Unmet Needs
14. Graves Disease Market Drivers and Barriers
16. About DelveInsight
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States